Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zbigniew Rudzki

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Blood|March 8, 2003
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisSusan Branford, Zbigniew Rudzki, Sonya Walsh, et al.
Clinical Endocrinology|November 21, 2008
Familial vasopressin-sensitive ACTH-independent macronodular adrenal hyperplasia (VPs-AIMAH): clinical studies of three kindredsLucia Gagliardi, Cheri Hotu, Graeme Casey, et al.
The New England Journal of Medicine|October 10, 2003
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaTim P Hughes, Jaspal Kaeda, Susan Branford, et al.
Haematologica|March 28, 2008
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish familyKun Liu, Robert Kralovics, Zbigniew Rudzki, et al.
Leukemia Research Reports|July 3, 2020
First case of near haploid philadelphia negative B-Cell acute lymphoblastic leukaemia relapsing as acute myeloid leukemia following allogeneic hematopoietic stem cell transplantationClaire Horgan, Charalampos Kartsios, Emmanouil Nikolousis, et al.
Blood|August 27, 2010
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivoVictoria J Weston, Ceri E Oldreive, Anna Skowronska, et al.
The American Journal of Surgical Pathology|July 25, 2022
MUM1/IRF4 is Highly Expressed in Dermatopathic Lymphadenopathy: Potential Utility in Diagnosis and Differential DiagnosisSofia Garces, Zbigniew Rudzki, C Cameron Yin, et al.
Disease Models & Mechanisms|September 24, 2015
T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid miceCeri E Oldreive, Anna Skowronska, Nicholas J Davies, et al.
Case Reports in Hematology|January 29, 2021
Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy AlterationsMaria Kaparou, Zbigniew Rudzki, Hannah Giles, et al.
Blood|July 17, 2004
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutationsSusan Branford, Zbigniew Rudzki, Ian Parkinson, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Blood|March 8, 2003
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisSusan Branford, Zbigniew Rudzki, Sonya Walsh, et al.
Clinical Endocrinology|November 21, 2008
Familial vasopressin-sensitive ACTH-independent macronodular adrenal hyperplasia (VPs-AIMAH): clinical studies of three kindredsLucia Gagliardi, Cheri Hotu, Graeme Casey, et al.
The New England Journal of Medicine|October 10, 2003
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaTim P Hughes, Jaspal Kaeda, Susan Branford, et al.
Haematologica|March 28, 2008
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish familyKun Liu, Robert Kralovics, Zbigniew Rudzki, et al.
Leukemia Research Reports|July 3, 2020
First case of near haploid philadelphia negative B-Cell acute lymphoblastic leukaemia relapsing as acute myeloid leukemia following allogeneic hematopoietic stem cell transplantationClaire Horgan, Charalampos Kartsios, Emmanouil Nikolousis, et al.
Blood|August 27, 2010
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivoVictoria J Weston, Ceri E Oldreive, Anna Skowronska, et al.
The American Journal of Surgical Pathology|July 25, 2022
MUM1/IRF4 is Highly Expressed in Dermatopathic Lymphadenopathy: Potential Utility in Diagnosis and Differential DiagnosisSofia Garces, Zbigniew Rudzki, C Cameron Yin, et al.
Disease Models & Mechanisms|September 24, 2015
T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid miceCeri E Oldreive, Anna Skowronska, Nicholas J Davies, et al.
Case Reports in Hematology|January 29, 2021
Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy AlterationsMaria Kaparou, Zbigniew Rudzki, Hannah Giles, et al.
Blood|July 17, 2004
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutationsSusan Branford, Zbigniew Rudzki, Ian Parkinson, et al.
Pageof 6